Does Timing of Cytoreductive Nephrectomy Impact Patient Survival With Metastatic Renal Cell Carcinoma in the Tyrosine Kinase Inhibitor Era? A Multi-institutional Study
Open Access
- 14 February 2013
- Vol. 81 (4), 805-812
- https://doi.org/10.1016/j.urology.2012.10.054
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted TherapyJournal of Urology, 2010
- Prospective Clinical Trial of Preoperative Sunitinib in Patients With Renal Cell CarcinomaJournal of Urology, 2010
- Presurgical Targeted Therapy with Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma: Clinical Results and Histopathological Therapeutic EffectsJapanese Journal of Clinical Oncology, 2010
- EORTC-GU group expert opinion on metastatic renal cell cancerEuropean Journal Of Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Response of the Primary Tumor to Neoadjuvant Sunitinib in Patients With Advanced Renal Cell CarcinomaJournal of Urology, 2008
- Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigmBJU International, 2008
- Mechanisms of adverse effects of anti-VEGF therapy for cancerBritish Journal of Cancer, 2007
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003